Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients.

Area of Science:

• Oncology
• Surgical Oncology
• Genetics

Background:

• Contralateral risk-reducing mastectomy (CRRM) is recommended for high-risk breast cancer patients, particularly those with BRCA1, BRCA2, or P53 mutations.
• Genetic mutations account for only 20-30% of familial breast cancer risk, raising questions about CRRM in genetically negative cases.
• Rising CRRM rates contrast with its unclear impact on overall survival for unilateral sporadic breast cancer.

Purpose of the Study:

• To evaluate the indications and ethical considerations of CRRM in young, unilateral breast cancer patients with negative genetic assessments.
• To determine if CRRM improves overall survival in women with unilateral sporadic breast cancer.
• To explore patient preferences and individual breast cancer features in the CRRM decision-making process.

Main Methods:

• Review of current clinical practices and ethical considerations regarding CRRM.
• Analysis of survival data for patients undergoing CRRM for unilateral breast cancer.
• Discussion of genetic risk assessment and its limitations in predicting contralateral cancer risk.

Main Results:

• CRRM does not appear to improve overall survival in women with unilateral sporadic breast cancer.
• The decision for CRRM should integrate patient preferences and individual tumor characteristics, not solely rely on genetic status.
• Surgeons should avoid advocating CRRM as a primary approach, except in highly anxious patients.

Conclusions:

• CRRM decision-making requires a nuanced approach, balancing potential benefits against the lack of proven survival advantage in many cases.
• Further prospective studies are essential to identify specific patient cohorts who may benefit most from CRRM.
• Ethical considerations regarding the removal of a healthy contralateral breast must be carefully weighed against patient concerns and individual risk profiles.